Ocean biomedical, inc. announces receipt of nasdaq staff determination letter

Providence, rhode island, oct. 22, 2024 (globe newswire) -- ocean biomedical, inc. (nasdaq: ocea), today announced that on october 16, 2024, it received a staff determination letter from the nasdaq stock market llc (“nasdaq”) stating that on april 18, 2024, may 22, 2024, and august 19, 2024, staff notified the company that it did not comply with nasdaq's filing requirements set forth in listing rule 5250(c)(1) (the “rule”) because it had not filed its form 10-k for the year ended december 31, 2024 (the “form 10-k”), and its forms 10-q for the periods ended march 31, 2024 and june 30, 2024 (the “forms 10-q”), respectively. based on its review and the materials submitted on june 17, 2024 and august 27, 2024, staff granted the company an exception until october 14, 2024, to regain compliance with the rule. upon further review, staff determined that the company did not meet the terms of the exception. specifically, the company has not filed the either its form 10-k or forms 10-q as required by the rule. the company will appeal staff's determination to a hearings panel (the “panel”), pursuant to the procedures set forth in the nasdaq listing rule 5800 series.
NDAQ Ratings Summary
NDAQ Quant Ranking